Chinese Regulator Flags Synopsys Acquisition of Ansys
By Dean Seal
China's market regulator is looking into Synopsys' proposed $35 billion acquisition of Ansys, the company said Thursday.
The chip software maker disclosed in a regulatory filing that earlier this week, China's State Administration for Market Regulation took the position that Synopsys must have the tie-up cleared by regulators before it can go forward, even though the transaction falls below China's merger notification thresholds.
Synopsys said it is working with Ansys on next steps and that the deal is expected to close in the first half of 2025, assuming it receives approval from Ansys shareholders and regulators.
The company said in January that it had agreed to buy Ansys in a cash-and-stock deal that would provide Ansys shareholders with $197 in cash and 0.345 share of Synopsys stock per share of Ansys.
The acquisition would extend Synopsys' reach in simulation software for designers of microchips, cars and airplanes. It is currently one of two big players in the space for software that chip makers use to lay out and test circuitry prior to manufacturing.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 16, 2024 10:00 ET (14:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software